Abbvie ((ABBV)), Abbvie (($CC:ABBV.CUR)) announced an update on their ongoing clinical study.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
AbbVie is conducting a Phase 1/2 clinical study titled A Phase 1/2, Open-Label, Platform Study to Evaluate Safety and Efficacy of the BCL-2 Inhibitor ABBV-453 Given as Monotherapy or in Combination With Antimyeloma Regimens in Subjects With Multiple Myeloma. The study aims to assess the safety and efficacy of ABBV-453 in adult participants with relapsed/refractory multiple myeloma (R/R MM), focusing on adverse events and changes in disease activity.
The study is testing the investigational drug ABBV-453, both as a monotherapy and in combination with other antimyeloma agents such as daratumumab, dexamethasone, and pomalidomide. The goal is to determine the optimal dosing and assess the drug’s effectiveness in treating R/R MM.
This interventional study is randomized and follows a sequential intervention model without masking, primarily aimed at treatment. Participants will receive various combinations of the drugs over a 4.5-year period, with frequent medical assessments to monitor treatment effects.
The study began on July 23, 2025, with primary completion expected in the future. The last update was submitted on July 29, 2025. These dates are crucial for tracking the study’s progress and potential impact on AbbVie’s pipeline.
The ongoing study could influence AbbVie’s stock performance and investor sentiment, particularly if ABBV-453 shows promising results. It may also impact the competitive landscape in the treatment of multiple myeloma, where other companies are developing similar therapies.
The study is ongoing, with further details available on the ClinicalTrials portal.